Savara Inc. (YB4P)
XSTU 
Summary
YB4P Chart
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal near-term catalyst.
Here's Why You Should Add Savara Stock to Your Portfolio Now
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, with MOLBREEVI targeting autoimmune PAP. SVRA's cash runway extends into H2 2027, bolstered by $203M in liquidity and up to $150M in non-dilutive capital upon FDA approval. Regulatory momentum is strong: MOLBREEVI has Priority Review, with a PDUFA date set for November 22, 2026, and positive Phase 3 data supporting efficacy.
Savara Inc. (YB4P) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Savara Inc. ever had a stock split?
Savara Inc. Profile
| Biotechnology Industry | Healthcare Sector | Matthew Pauls CEO | XSTU Exchange | 805111101 CUSIP |
| US Country | 70 Employees | - Last Dividend | 28 Apr 2017 Last Split | 1 Jun 2017 IPO Date |
Overview
Savara Inc. is a clinical-stage biopharmaceutical company that is dedicated to the development of novel therapies for rare respiratory diseases. The company is actively engaged in the research and development of groundbreaking treatments to address unmet medical needs within this niche field. With its headquarters in Langhorne, Pennsylvania, Savara Inc. positions itself at the forefront of biopharmaceutical innovation, focusing on conditions that have historically been overlooked or inadequately addressed by the broader medical community. Their commitment to tackling rare respiratory diseases is underscored by their advancement of key product candidates through the clinical development process, aiming to bring much-needed therapies to the market.
Products and Services
The primary product candidate that Savara Inc. is developing is:
- Molgramostim: An inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) that is currently in the Phase 3 development stage. Molgramostim represents a pioneering approach to treating autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant within the alveoli, leading to difficulty in breathing. By utilizing the therapeutic potential of GM-CSF, molgramostim aims to stimulate the patient's immune system to clear the excess surfactant, thereby improving respiratory function. As the lead candidate, molgramostim's development underscores Savara Inc.'s commitment to addressing the complexities of rare respiratory diseases with innovative solutions.
